Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772289 | 0.81 | MCL1 (0.44) | SCN10ASLC22A12 | |
| SCHEMBL4778161 | 0.81 | HCAR2 (0.47) | CYP11B2PIK3CGCYP11B1 | |
| SCHEMBL4775928 | 0.81 | F11 (0.54) | SLC22A12F11PIN1XDH | |
| SCHEMBL3090482 | 0.80 | ALOX15 (0.41) | F11PIN1 | |
| SCHEMBL31031756 | 0.78 | HCAR2 (0.45) | CYP11B2PIK3CGCYP11B1 | |
| SCHEMBL4772383 | 0.78 | HCAR2 (0.45) | CYP11B2PIK3CGCYP11B1 | |
| SCHEMBL4775929 | 0.78 | MCL1 (0.38) | — | |
| SCHEMBL1793266 | 0.78 | NPC1 (0.50) | — | |
| SCHEMBL4779431 | 0.77 | HCAR2 (0.39) | — | |
| SCHEMBL1794776 | 0.77 | LRRK2 (0.47) | PIK3CGKCNH2SCN10APOLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | GRM2, GRM1, GRM3 | CYP11B2 2896/4885PIK3CG 2974/4885CYP11B1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.